ProJect Pharmaceutics (PJP), a company specializing in formulation and process development for parenteral drug products, has extended its safety facilities with laboratories dedicated to handle GMO S2 and BSL-2 based biologic products, such as live virus vaccines, protective and therapeutic vaccines, as well as gene and cell therapy products.

The GMO S2 and BSL-2 safety lab is equipped with a dedicated pilot freeze dryer to design tailored lyophilization cycles. Also, analytical high-throughput methods have been implemented in order to select the most effective combination of excipients for the final drug product to maintain the active quaternary structure of a virus capsid and avoiding aggregation, even under stress conditions like elevated temperature, freezing and freeze drying, according to the company.

PJP provides smart formulations and manufacturing processes for virus vaccines or other classified drug products in their dedicated labs in compliance with mandatory safety requirements up to GMO S2 and BSL-2 classification.